Related Experiment Video
Updated: Jun 29, 2026

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus (MRSA) in Rat
Published on: June 4, 2012
Clinical experience with daptomycin: bacteraemia and endocarditis
1Division of General Internal Medicine, Wayne State University, University Health Center, Detroit, MI 48201, USA. dlevine@med.wayne.edu
Abstract:
Serious infections due to Staphylococcus aureus, especially those due to methicillin-resistant S. aureus, have become a major challenge. Vancomycin has long been the drug of choice for treatment of such infections, but failures due to its slow bactericidal activity coupled with increasing MICs have necessitated a search for new, more effective agents. Daptomycin has been studied by a number of investigators and has proved to be effective for bacteraemic infections due to staphylococci as well as vancomycin-resistant enterococci and other Gram-positive organisms. In addition, in a randomized controlled trial comparing daptomycin monotherapy with potentially synergistic therapy with either vancomycin or beta-lactam, both used in combination with an aminoglycoside, daptomycin achieved comparable outcomes but with significantly less nephrotoxicity.
Insights
Daptomycin is an effective treatment for serious Staphylococcus aureus infections, including methicillin-resistant strains. This antibiotic shows comparable outcomes to vancomycin with reduced kidney toxicity.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Serious Staphylococcus aureus infections, particularly methicillin-resistant S. aureus (MRSA), pose a significant clinical challenge.
- Vancomycin, the traditional treatment, exhibits slow bactericidal activity and increasing minimum inhibitory concentrations (MICs), driving the need for alternative therapies.
Purpose of the Study:
- To evaluate the efficacy and safety of daptomycin as a treatment for Gram-positive bacterial infections.
- To compare daptomycin's outcomes and nephrotoxicity against vancomycin or beta-lactam in combination with an aminoglycoside.
Main Methods:
- Review of studies investigating daptomycin for various Gram-positive infections.
- Analysis of a randomized controlled trial comparing daptomycin monotherapy with combination therapies.
Main Results:
- Daptomycin demonstrated efficacy in treating bacteremic infections caused by staphylococci and vancomycin-resistant enterococci.
- The randomized trial showed daptomycin achieved outcomes comparable to vancomycin/beta-lactam plus aminoglycoside.
- Daptomycin exhibited significantly lower nephrotoxicity compared to the combination therapies.
Conclusions:
- Daptomycin represents a promising alternative for treating serious Gram-positive infections, including MRSA.
- Its favorable safety profile, particularly reduced nephrotoxicity, makes it a valuable therapeutic option.
Related Concept Videos
Endocarditis I: Introduction
Endocarditis II: Clinical Features of Infective Endocarditis
Endocarditis III: Medical Management
Endocarditis IV: Nursing Management
Diphtheria
Clinical Significance of Antibiotic Resistance
